Efficacy and safety of Crizotinib in patients with ALK positive non small cell lung cancer (NSCLC): Real-world findings.

Cristina Azpitarte-Raposeiras,N. Alvarez,Jorge García,María Carmen Areses Manrique,Natalia Fernández Núñez,F.J. Afonso,Margarita Amenedo,Nazaret Quiroga Veiga,Victor Cebey,Martin Lázaro Quintela,J.L. Firvida,Begona Campos Balea,Juan Ruiz-Bañobre,Vanesa Varela Pose,Sara Agraso Busto,Manuel Constenla

Efficacy and safety of Crizotinib in patients with ALK positive non small cell lung cancer (NSCLC): Real-world findings.

2019

Cristina Azpitarte-Raposeiras
N. Alvarez
Jorge García
María Carmen Areses Manrique
Natalia Fernández Núñez
F.J. Afonso
Margarita Amenedo
Nazaret Quiroga Veiga
Victor Cebey
Martin Lázaro Quintela
J.L. Firvida
Begona Campos Balea
Juan Ruiz-Bañobre
Vanesa Varela Pose
Sara Agraso Busto
Manuel Constenla

e20636Background: First or second line crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with NSCLC ALK positive and it was the first approved ALK inhibitor. Ho...

Keywords:

non-small cell lung cancer (NSCLC)
ALK-Positive
Pathology
Crizotinib
Oncology
Medicine
Internal medicine
ALK inhibitor
in patient
Clinical trial
second line
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations